Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2016, Vol. 43 Issue (5): 673-677    DOI: 10.12891/ceog2164.2016
Original Research Previous articles | Next articles
First trimester maternal serum PAPP-A levels and associated pregnancy complications in intrahepatic cholestasis of pregnancy
G. Aksan Desteli1, *(), N. Şahin-Uysal2, T. Çok3, Ç. Gülümser2, H. Kalaycı3, F. F. Yanık2
1Department of Obstetrics and Gynecology, Baskent University İstanbul Hospital, Istanbul
2Department of Obstetrics and Gynecology, Baskent University Ankara Hospital, Ankara
3Department of Obstetrics and Gynecology, Baskent University Adana Hospital, Adana (Turkey)
Download:  PDF(76KB)  ( 9 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose: To investigate first trimester maternal serum pregnancy associated plasma protein A (PAPP-A) multiple of the median (MoM) in cases with intrahepatic cholestasis of pregnancy (ICP). Obstetric complications and relation with PAPP-A MoM were also evaluated. Materials and Methods: This was a retrospective case-control study. After exclusions, for each ICP case, two controls with uncomplicated singleton pregnancies were randomly selected. PAPP-A MoM of ICP cases with and without obstetric complications, and the control group were compared with each other. Results: Total incidence of ICP was 0.99 % (138/13988). The study included 113 singleton pregnant women. Rates of gestational diabetes mellitus (GDM), preeclampsia (PE), fetal growth restriction (FGR), preterm labor (PTL), and hypothyroidism in cases with ICP were 21.2%, 7.9%, 10.6%, 18.6%, and 5.3%, respectively. Median PAPP-A MoM were 0.93 in ICP group and 1.10 in control group (p > 0.05). PAPP-A MoM levels were not significantly different either between the ICP group with complicated pregnancies and the control group or between the ICP group without complicated pregnancies and the control group (p > 0.05). Conclusion: ICP incidence was similar to other European countries. Rates of obstetric complications expecially GDM were higher than expected in general pregnant population. ICP is not considered as pregnancy complications that have low PAPP-A MoM levels.
Key words:  Intrahepatic cholestasis of pregnancy      PAPP-A      Adverse pregnancy outcome     
Published:  10 October 2016     
*Corresponding Author(s):  G. AKSAN DESTELI     E-mail:  guldenizdesteli@hotmail.com

Cite this article: 

G. Aksan Desteli, N. Şahin-Uysal, T. Çok, Ç. Gülümser, H. Kalaycı, F. F. Yanık. First trimester maternal serum PAPP-A levels and associated pregnancy complications in intrahepatic cholestasis of pregnancy. Clinical and Experimental Obstetrics & Gynecology, 2016, 43(5): 673-677.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog2164.2016     OR     https://ceog.imrpress.com/EN/Y2016/V43/I5/673

[1] Sotirios Sotiriou, Maria Satra, Dimitra N. Vamvakopoulou, Chrisostomos Sofoudis, Aikaterini Simou, Thomas Kilindris, Andreas Sidiropoulos, Konstantinos V. Kakavas, Antonis Garas, Hara Skentou, Nikos C. Vamvakopoulos, Alexandros Daponte. Maternal serum pregnancy-associated plasma protein-A concentration at 11–14 weeks of gestation of women with common congenital anatomic uterine abnormalities[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 343-346.
[2] C. Chollet, B. Andre, M. Voglimacci, A. Ghassani, O. Parant, P. Guerby. Perinatal outcomes of second trimester antenatal genital bleeding[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(1): 105-110.
[3] O. Temizkan, B. Aydogan, B. Arıcı, O. Aşıcıoğlu, P. Yalcin. First trimester maternal serum marker in intrahepatic cholestasis of pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(4): 595-598.
[4] B.S. Unlu, H. Energin, Y. Yildiz, E. Unlu, E.G. Yapar Eyi. Maternal serum pregnancy-associated plasma protein-A levels in hyperemesis gravidarum: a prospective case control study[J]. Clinical and Experimental Obstetrics & Gynecology, 2014, 41(5): 534-536.
[5] Z. Saruhan, M. Ozekinci, M. Simsek, I. Mendilcioglu. Association of first trimester low PAPP-A levels with adverse pregnancy outcomes[J]. Clinical and Experimental Obstetrics & Gynecology, 2012, 39(2): 225-228.
[6] G. Androutsopoulos, P. Gkogkos, V. Papadopoulos, G. Adonakis, V. Tsapanos, P. Vassilakos, G. Panayiotakis, G. Decavalas. Mid-trimester maternal serum markers in predicting adverse pregnancy outcome[J]. Clinical and Experimental Obstetrics & Gynecology, 2009, 36(4): 237-240.
[7] G. Androutsopoulos, P. Gkogkos, P. Vassilakos, G. Panayiotakis, G. Decavalas. Mid-trimester maternal serum hCG levels in predicting adverse pregnancy outcome[J]. Clinical and Experimental Obstetrics & Gynecology, 2009, 36(3): 173-175.
[8] P. Gkogkos, G. Androutsopoulos, P. Vassilakos, G. Panayiotakis, G. Kourounis, G. Decavalas. Mid-trimester maternal serum AFP levels in predicting adverse pregnancy outcome[J]. Clinical and Experimental Obstetrics & Gynecology, 2008, 35(3): 208-210.
[9] R. Axt-Fliedner. Second trimester uterine artery Doppler ultrasound as a screening test for adverse pregnancy outcome[J]. Clinical and Experimental Obstetrics & Gynecology, 2004, 31(1): 9-11.
No Suggested Reading articles found!